NaturalVue Multifocal for Presbyopia

Phase-Based Progress Estimates
VTI, Alpharetta, GA
NaturalVue Multifocal - Device
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new contact lens that provides clear distance, intermediate, and near vision. The goal is to quantify the benefits of this new lens design. The primary endpoint of this trial is the mean change in the distance-corrected near visual acuity from baseline over the course of the study.This trial is testing NaturalVue Multifocal to see if it is effective in treating Presbyopia. There is no placebo group in this trial, which means that all participants will be receiving the treatment. NaturalVue Multifocal has already been approved by the FDA for another condition, so this trial is investigating whether it can be effective for Presbyopia as well. The primary endpoint of this trial is the mean change in the distance-corrected near visual acuity from

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 4 hours

4 hours
LogMAR Visual Acuity

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: NaturalVue Multifocal · No Placebo Group · Phase 4

Experimental Group · 1 Intervention: NaturalVue Multifocal · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 hours
Closest Location: VTI · Alpharetta, GA
Photo of georgia 1Photo of georgia 2Photo of georgia 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Presbyopia
0 CompletedClinical Trials

Who is running the clinical trial?

Visioneering Technologies, IncLead Sponsor
2 Previous Clinical Trials
224 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.